2013 Fiscal Year Final Research Report
Comprehensive analyses for the mechanism of PIVKA-II production from hepatocellular carcinoma
| Project/Area Number |
23591005
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Research Institute, International Medical Center of Japan |
|---|
Principal Investigator |
MURATA Kazumoto 独立行政法人国立国際医療研究センター, その他部局等, その他 (40345971)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IMAMURA Masatoshi 国立国際医療研究センター, 国府台病院, 医長 (60445129)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 肝癌 / 腫瘍マーカー / PIVKA-II |
|---|
| Research Abstract |
PIVKA-II is generally used in hepatocellular carcinoma (HCC) clinic, but precise mechanism of PIVKA-II production is still unkown. We have demonstrated that PIVKA-II was produced when HCC became metastatic phenotype (epithelial mesenchymal transition: EMT) that was impaired uptake of vitamin K by actin rearrangement. In this project, we demonstrated that further EMT caused impairment of liver specific protein synthesis, resulting in impairment of PIVKA-II production even though HCC still grew. Moreover, findings in enhanced ultrasonography well-correlated with PIVKA-II production in surgically resected HCC. Taken together, PIVKA-II could be an biological marker for HCC as well as a tumor marker of HCC.
|
-
[Journal Article] Human BDCA3(+) dendritic cells are a potent producer of IFN-λin response to hepatitis C virus2013
Author(s)
Yoshio S, Kanto T, Kuroda S, Matsubara T, Higashitani K, Kakita N, Ishida H, Hiramatsu N, Nagano H, Sugiyama M, Murata K, Fukuhara T, Matsuura Y, Hayashi N, Mizokami M, Takehara T.
-
Journal Title
Hepatology
Volume: 57
Pages: 1705-1715
DOI
-
-
-
[Journal Article] Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity2012
Author(s)
Zeissig S, Murata K, Sweet L, Publicover J, Hu Z, Kaser A, Bosse E, Hussain MM, Balschun K, Rocken C, Arlt A, Gunther R, Hampe J, Schreiber S, Baron JL, Moody DB, Liang TJ, Blumberg RS.
-
Journal Title
Nat Med
Volume: 18
Pages: 1060-1068
DOI
-
[Journal Article] Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients2012
Author(s)
Saito H, Ito K, Sugiyama M, Matsui T, Aoki Y, Imamura M, Murata K, Masaki N, Nomura H, Adachi H, Hige S, Enomoto N, Sakamoto N, Kurosaki M, Mizokami M, Watanabe S.
-
Journal Title
Hepatol Res
Volume: 42
Pages: 958-965
DOI
-
-
[Journal Article] LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients2012
Author(s)
Ito K, Kuno A, Ikehara Y, Sugiyama M, Saito H, Aoki Y, Matsui T, Imamura M, Korenaga M, Murata K, Masaki N, Tanaka Y, Hige S, Izumi N, Kurosaki M, Nishiguchi S, Sakamoto M, Kage M, Narimatsu H, Mizokami M.
-
Journal Title
Hepatology
Volume: 56
Pages: 1448-1456
DOI
-
[Journal Article] Th rs8099917 polymorphism, determined by a suitable genotyping method, is a better predictor for response to pegylated interferon-/ribavirin therapy in Japanese patients than other SNPs associated with IL28B2011
Author(s)
Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, Murata K, Nomura H, Hige S, Adachi H, Hino K, Yatsuhashi H, Orito E, Kani S, Tanaka Y, Mizokami M.
-
Journal Title
J Clin Microbiol
Volume: 49
Pages: 1853-1860
DOI
-
[Journal Article] Phenotype-dependent production of des--carboxy prothrombin in hepatocellular carcinoma2011
Author(s)
Suzuki H, Murata K, Gotoh T, Kusano M, Okano H, Oyamada T, Yasuda Y, Imamura M, Kudo M, Mizokami M, Sakamoto A.
-
Journal Title
J Gastroenterol
Volume: 46
Pages: 1219-29
DOI
-
[Journal Article] Easy-to-use phylogenetic analysis system for hepatitis B virus infection2011
Author(s)
Sugiyama M, Inui A, Shin-I T, Komatsu H, Mukaide M, Masaki N, Murata K, Ito K, Nakanishi M, Fujisawa T, Mizokami M.
-
Journal Title
Hepatol Res
Volume: 41
Pages: 936-45
DOI
-
-
[Presentation] Different amount of IFN-l3 determines the outcome of Peg-IFN/RBV therapy in HCV patients2012
Author(s)
Murata K, Sugiyama M, Kimura T, Yoshio S, Kanto T, Asano M, Aoki Y, Takeda T, Korenaga M, Imamura M, Masaki N, Mizokami M.
Organizer
The 10^<th> JSH Single Topic Conference"Hepatitis C : Best Practice Based on Science
Place of Presentation
Tokyo
Year and Date
20121121-22
-
[Presentation] Interferon-λ3 determines response to pegylated interferon/ribavirin therapy in chronic hepatitis C2012
Author(s)
Murata K, Sugiyama M, Kimura T, Yoshio S, Kanto T, Aoki Y, Hiramine S, Matsui T, Korenaga M, Imumura M, Masaki N, Mizokami M.
Organizer
The 63^<th> annual meeting of the American association for the study of liver diseases
Place of Presentation
Boston
Year and Date
20121109-13
-
-
-
-
-
-
